Most Read This Week
- SH-1028, a Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR T790M–Positive NSCLC
- Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
- Effect of Smoking Habits on the Efficacy of EGFR TKI Plus Anti-Angiogenic Agent in Advanced EGFR-Mutant NSCLC
- Clinical Outcomes of Icotinib-Treated Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by ctDNA Testing
- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations
Recently Updated
- Characterizing the Clinicopathologic, Genomic, and Immunophenotypic Correlates of KRASG12D-Mutated NSCLC
- Clinical Outcomes of Icotinib-Treated Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by ctDNA Testing
- Poziotinib for EGFR Exon 20–Mutant NSCLC
- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations
- Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations